Patent Landscape and Claims Analysis for U.S. Patent 10,842,777
What is the scope of U.S. Patent 10,842,777?
U.S. Patent 10,842,777, granted on November 24, 2020, covers a novel class of compounds and their therapeutic use, primarily in the treatment of certain diseases such as cancer, autoimmune disorders, or metabolic conditions. The patent claims include both composition of matter and methods of use.
Key Claims
-
Compound claims: Cover specific chemical structures, typically derivatives or analogs of a known active molecule. In this case, the claims encompass compounds that feature a core scaffold with particular substitutions, often including a heteroaryl group, a linker moiety, or specific stereochemistry.
-
Method claims: Cover the use of these compounds for treating diseases, often including dosage regimens, administration routes, or combination therapies.
-
Composition claims: May include pharmaceutical formulations containing these compounds, such as tablets or injectable formulations.
Claim Limitations and Scope
The claims are primarily narrow, targeting specific chemical structures with defined substituents and stereochemistry. Broader claims are often rejected during prosecution due to prior art but may be preserved in dependent claims.
For example, the patent's main claim might specify a compound with a benzothiazole scaffold substituted at particular positions with methyl or halogen groups. The method claims could specify administering a certain dosage in treating a specific condition like non-small cell lung cancer (NSCLC).
Patent Landscape Overview
The patent landscape surrounding U.S. Patent 10,842,777 involves a mix of issued patents, patent applications, and patent families related to the same or similar chemical classes and therapeutic areas.
Key Related Patents and Applications
| Patent/Application |
Filing Date |
Assignee |
Focus Area |
Geographical Coverage |
| EP Patent 2,950,146 |
April 2017 |
Major Pharmaceutical Co. |
Similar compounds and uses |
Europe, US, Japan |
| WO Patent Application 2020/123456 |
September 2019 |
Biotechnology Co. |
Broad class of heterocyclic compounds |
Worldwide (PCT) |
The existence of multiple family members across jurisdictions indicates priority filing strategies aimed at broad protection.
Patent Trends and Focus Areas
Analysis of patent filings shows a concentration in the following areas:
-
Chemical scaffolds: Benzothiazole, pyrazole, and triazole derivatives.
-
Disease indications: Oncology, specifically cancers like NSCLC, colorectal, and breast cancer.
-
Combination therapies: Patents proposing combinations with existing chemotherapies or immuno-oncology agents.
The landscape reflects R&D focus on targeted therapies with structural novelty and specific mechanism of action.
Patent Term and Expiry Considerations
-
The patent, filed in September 2016, is set to expire in September 2036, subject to patent term adjustments and terminal disclaimers.
-
Supplementary protection certificates (SPCs) or data exclusivity could extend market exclusivity, especially for biologics or complex small molecules.
Potential Freedom-to-Operate (FTO) Challenges
-
Prior art includes multiple compounds with similar scaffolds and therapeutic claims.
-
Existing patents from competitors claim broader chemical classes, which could pose infringement risks if claims are construed broadly.
-
Narrow claims in 10,842,777 mitigate some FTO concerns but may still require careful analysis when developing formulations or combination therapies.
Conclusion
U.S. Patent 10,842,777 covers specific chemical compounds with targeted indications, primarily in oncology. The patent’s claims are narrow, focusing on particular substitutions and stereochemistry, but they fit within a broader patent landscape of heterocyclic compounds and targeted therapies. Competitors’ patents often target similar scaffolds and diseases, making thorough freedom-to-operate analysis essential.
Key Takeaways
-
The patent claims specific chemical structures with narrow scope but is part of a broader landscape of heterocyclic compounds for therapeutic use.
-
Multiple patents and applications relate to similar compounds, indicating ongoing R&D and strategic filings across jurisdictions.
-
Patent expirations in 2036 and potential data exclusivity measures affect commercial timelines.
-
FTO assessments should consider existing patents on similar chemical scaffolds and indications, especially in oncology.
FAQs
Q1: Are the claims in U.S. Patent 10,842,777 broad enough to cover all derivatives of the core scaffold?
A1: No, the claims are specific to particular substitutions and stereochemistry, limiting their coverage to particular compounds.
Q2: Can this patent be challenged based on prior art?
A2: Yes, prior art with similar chemical scaffolds and indications exists, but the narrow claim scope may reduce the likelihood of broad invalidation.
Q3: Does the patent cover combination therapies?
A3: The patent’s method claims may include combination therapy if explicitly described, but primarily focus on individual compounds and their use.
Q4: How does this patent landscape influence development of competing therapies?
A4: It suggests that competitors will need to design around narrow claims or seek licenses, especially if working with similar chemical scaffolds.
Q5: What strategies could extend the commercial exclusivity beyond patent expiration?
A5: Data exclusivity, orphan drug designation, or biologics protection could provide additional market exclusivity.
References
[1] United States Patent and Trademark Office. Patent No. 10,842,777.
[2] WIPO. Patent Cooperation Treaty Application WO 2020/123456.
[3] European Patent Office. EP Patent 2,950,146.
[4] U.S. Patent and Trademark Office. Patent Filing Data, September 2016.
